PCSK9联合乳酸及SOFA评分对脓毒症患者死亡风险的 预测价值
2025-08-12严妍邓紫薇仇成凤



中图分类号:R631 文献标志码:A DOI:10.11958/20250460
Predictive value PCSK9 combined with lactate acid SOFA score for mortality risk in patients with sepsis
YAN Yan1,DENG Ziwei2, QIU Chengfeng2,3△
1nd, ,418ooo,;2 ,3 , Hospital Corresponding Author E mail: qiuchengfeng0721@163.com
Abstract:ObjectiveTo assess the predictive value proprotein convertase subtilisin/kexin type-9 (PCSK9) combined with lactic acid(Lac)Sequential Organ Failure Assessment (SOFA)score indetermining the28-day mortality risk patients withsepsis.MethodsAtotal 2O3 patients withsepsis werefolowedupfor28days.Patients weredivided into the death group ( n =56) the survival group ( n=147 )according to the clinical outcome. The general data clinical indicators were compared between thetwo groups.The prediction model 28daymortalityrisk sepsis patients was established bymultivariateLogisticregresionanalysis,the nomogramtheprediction modelvisualization wasdrawn. ResultsAlanine aminotransferase,serumcreatinine,bloodurea nitrogen,Lac,PCSK9SOFAscore were higherin the death group than those in the survival group ( Plt;0.05 ), while the hemoglobin level was lower than that in the survival group ( Plt;0.05 ).The multivariable Logistic regressionanalysis identified that elevated levels Lac (OR=1.197,95%Cl:1.019- 1.435),PCSK9(OR=1.002,95%CI: 1.001-1.003)SOFA score (OR=1.858,95%CI: 1.528-2.340)were independentrisk factors for 28-daymortality inpatientswith sepsis ( Plt;0.05 ).Nomogram was developed using these three indicators, the linear predictor cutf value was -1.06 .Patients were divided into the low-risk group (n=126) the high-risk group ( n= 77). The 28-day mortality rates were 4.0% for the low-risk group 66.2% for the high-risk group.Internal validation showed thatthe model with these three indicators had good discrimination (C-index=0.924,95%CI: 0.881\~0.960, Plt;0.05 ) calibration (χ2=11.543 , Pgt;0.05 ) clinical utility.Conclusion The combination serum PCSK9,Lac SOFA scores at admission effectively predicts 28-daymortality risk in sepsis patients.
KeyWords:sepsis; organ dysfunction scores; lactic acid; PCSK9; 28-day mortality
尽管在过去的几十年里脓毒症的诊断和治疗水平取得了显著的进步,但重症监护病房该病的病死率仍然很高[1-2]。建立具有更高预测价值的模型对于改善脓毒症早期预后至关重要。已有研究开发了几项预测工具来评估危重患者的结局[3-4],但由于脓毒症疾病的复杂性,这些工具预测准确度有限。因此,需要更准确的方法来预测患者的结局。生物标志物和临床预后标志物的组合在预测脓毒症病死率方面显示出巨大的优势[5-7]。一些文献报道,前蛋白枯草溶菌素-9(proprotein convertase subtilisin/kexintype-9,PCSK9)是脓毒症潜在的治疗靶点[8-10]。细胞实验显示,PCSK9大于 250μg/L 可降低肝细胞对脂多糖(LPS)的清除能力,降低幅度高达 60%[11] 类似地,抗PCSK9抗体可将家族性或非家族性高胆固醇血症患者的低密度脂蛋白胆固醇(LDL-C)水平降低 74%[12] 。而流行病学和遗传学研究也表明PCSK9和脓毒症预后有关[13-15]。然而,目前少有研究使用PCSK9联合其他临床经典预测因子预测脓毒症的病死率。因此,本研究探索联合使用PCSK9、乳酸(Lac)和序贯器官衰竭评估(SOFA)评分预测脓毒症患者28d死亡风险的可行性。
1对象与方法
1.1研究对象选取2020年3月—2021年9月在湖南医药学院总医院急诊科与重症医学科诊治的203例脓毒症患者。纳入标准:(1)年龄 gt;18 岁。(2)人院 24h 确诊并符合脓毒症Sepsis-3.0标准[16]。排除标准:(1)转诊患者。(2)入院48h内死亡者。(3)血液样本存在质量问题,如乳糜血的患者。本研究已获得湖南医药学院总医院医学伦理委员会批准(批号:KY-2019082203)。203例患者随访28d,根据临床转归分为死亡组( n=56 和存活组 n=147 )。……
